ArticleTherapeutic advances in hematology2012
Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.
Article in Therapeutic advances in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.Blood advances · 2022Trial
- Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone.ACS omega · 2026Article
- Iron-Responsive Deferasirox Release from Covalently Grafted Hydrogels on Microwires Extends Iron Chelation Time Scales.ACS applied materials & interfaces · 2026Article
- Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone.bioRxiv : the preprint server for biology · 2025Article
- Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia.Pharmacy (Basel, Switzerland) · 2025Article
- Intranasal delivery of iron chelators and management of central nervous system disease.Frontiers in pharmacology · 2025Review
- Broadening horizons: ferroptosis as a new target for traumatic brain injury.Burns & trauma · 2024Review
- Accelerated atherosclerosis in beta-thalassemia.American journal of physiology. Heart and circulatory physiology · 2023Article
- Quality by design approach for green HPLC method development for simultaneous analysis of two thalassemia drugs in biological fluid with pharmacokinetic study.RSC advances · 2022Article
- Effects of BJournal of magnetic resonance imaging : JMRI · 2022Article
- Vitamin and mineral supplementation for β-thalassemia during COVID-19 pandemic.Future science OA · 2020Review
- 3-Chloro-Frontiers in pharmacology · 2018Article
- Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.Journal of clinical and diagnostic research : JCDR · 2017Article
- A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.PloS one · 2015Article
- The ongoing pursuit of neuroprotective therapies in Parkinson disease.Nature reviews. Neurology · 2015Review
- Iron chelation and multiple sclerosis.ASN neuro · 2014Review
- Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.PloS one · 2014Article
- Acquired aplastic anemia in children.Pediatric clinics of North America · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deferiprone is an orally active iron-chelating agent used in the management of transfusion-related hemosiderosis. It has been in clinical use for over 20 years and has been shown to be effective in reducing cardiac iron load and improving cardiac function. As cardiac siderosis is the leading cause of death in patients with transfusion-dependent thalassemia, deferiprone helps to improve the overall prognosis of these patients. It is relatively well tolerated with gastrointestinal symptoms being the commonest side effects. Agranulocytosis (0.5%), neutropenia (9%), thrombocytopenia (up to 45%) and arthropathy (20%) are the most important side effects and may require discontinuation of therapy. Regular monitoring of blood counts is recommended for patients on deferiprone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.